Nicholas Gross, MS

Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

BACKGROUND: In the 12-week ARM-TD and AIM-TD studies of patients with tardive dyskinesia (TD), the percentage of patients achieving ≥50% and ≥70% responses (i.e. reductions from baseline ...

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Juha-Matti Savola , MD, PhD;

Nicholas Gross , MS;

Stewart Factor , DO;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Karen Anderson , MD;

11/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Nicholas Gross, MS

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products